Condition: Solid Tumors · Sponsor: Jacobio Pharmaceuticals Co., Ltd.
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
This description comes directly from the study's public registry record.
Jacobio Pharmaceuticals · 781-918-6670 · clinicaltrials@jacobiopharma.com
Always discuss trial participation with your own doctor first.
| Research Site | Denver, Colorado, United States | Recruiting |
| Research site | Lake Mary, Florida, United States | Terminated |
| Research site | St Louis, Missouri, United States | Recruiting |
| Research site | Canton, Ohio, United States | Terminated |
| Research site | Cleveland, Ohio, United States | Recruiting |
| Research Site | Nashville, Tennessee, United States | Recruiting |
| Research site | Houston, Texas, United States | Recruiting |
| Research Site | Beijing, Beijing Municipality, China | Recruiting |
| Research Site | Beijing, Beijing Municipality, China | Recruiting |
| Research Site | Beijing, Beijing Municipality, China | Recruiting |
| Research Site | Guangzhou, Guangdong, China | Recruiting |
| Research Site | Zhengzhou, Henan, China | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06386146